Navigation Links
Omeros Appoints David A. Mann to its Board of Directors

SEATTLE, Aug. 13 /PRNewswire/ -- Omeros Corporation has announced the appointment of David A. Mann to the Company's Board of Directors. Mr. Mann also serves as Chairman of the Board's audit committee.

"Dave's years of executive management experience in finance and operations in the biotechnology sector are an invaluable asset to Omeros," stated Gregory Demopulos, M.D., Chairman and CEO of Omeros. "He is an important addition to our Board, and I expect that he will play an integral role as we prepare for product commercialization."

"Dr. Demopulos and his team have done an excellent job in advancing their PharmacoSurgery platform, and I am pleased to be working with them," commented David Mann. "With a deep pipeline focused on inflammation and CNS, Omeros represents an exciting opportunity."

Mr. Mann brings with him over 20 years of executive management, finance and operations experience in the biotechnology industry. He was executive vice president and chief financial officer at Immunex prior to and during its acquisition by Amgen, and held senior financial positions at the Fred Hutchinson Cancer Research Center. Mr. Mann serves on the Board of Directors of Trubion Pharmaceuticals, and is on the advisory board of the Western Washington University College of Business and Economics and the Western Washington University Foundation Board. He is a former Certified Public Accountant, and earned his M.B.A. from the University of Washington and a B.A. from Western Washington University.

About Omeros Corporation

Omeros Corporation is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. Omeros' most clinically advanced product candidates are derived from its proprietary PharmacoSurgery(TM) platform designed to improve clinical outcomes of patients undergoing arthroscopic, ophthalmological, urological and other surgical and medical procedures. Omeros has four ongoing PharmacoSurgery(TM) clinical development programs, and its lead product candidate, OMS103HP, is being evaluated in Phase 3 clinical trials for use during arthroscopic surgery to improve postoperative joint function and reduce postoperative pain. Omeros is also building a diverse pipeline of preclinical programs targeting inflammation and central nervous system disorders. For more information on Omeros, visit the Company's Web site at

SOURCE Omeros Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Omeros Corporation Files Registration Statement for Proposed Initial Public Offering
2. Anthera Pharmaceuticals Completes $19 Million Financing; Appoints Christopher S. Henney as Chairman
3. SpineMark Appoints Dr. Rudolf Bertagnoli Chairman of International Medical Advisory Board
4. Marinus Pharmaceuticals Appoints John Krayacich as President and Chief Executive Officer
5. SAFC Appoints New Vice President of Quality and Regulatory Affairs
6. Anacor Pharmaceuticals Appoints Dr. Kurt Jarnagin Vice President of Biological Research
7. ARCA biopharma Appoints James Carr as Vice President of Marketing
8. China Biologic Products Establishes Audit Committee and Appoints Three New Independent Directors to Board of Directors
9. Health Monitoring Systems Appoints Karen S. Dockrell As VP, Sales
10. Human Genome Sciences Appoints David P. Southwell to its Board of Directors
11. Tengion Appoints Mark Stejbach Vice President of Marketing & Commercial Planning
Post Your Comments:
(Date:11/24/2015)... Nev. , Nov. 24, 2015  PDL BioPharma, Inc. ... P. McLaughlin , the company,s president and chief executive officer, ... Healthcare Conference next week in New York City ... occur on Tuesday, December 1, 2015 at 9:30 a.m. EST. ... Please connect to the website at least 15 minutes prior ...
(Date:11/24/2015)... ... ... Laboratories is pleased to announce that it has completed construction on a new ... 61, USP 62 and USP 51 testing specific to raw materials and will enable ... by one supplier. Management has formally announced that the facility will be ...
(Date:11/23/2015)... CHICAGO , Nov. 24, 2015 Women with ... screening CT exams face a higher risk of lung cancer ... being presented next week at the annual meeting of the ... --> --> Lung ... are classified as solid or subsolid based on their appearance ...
(Date:11/23/2015)... KONG, Nov. 23, 2015 China Cord Blood ... China,s leading provider of cord blood collection, laboratory testing, ... today announced its preliminary unaudited financial results for the ... ended September 30, 2015. --> ... , Revenues for the second quarter of fiscal ...
Breaking Biology Technology:
(Date:11/2/2015)... , Nov. 2, 2015  SRI International has ... to provide preclinical development services to the National Cancer ... SRI will provide scientific expertise, modern testing and support ... of preclinical pharmacology and toxicology studies to evaluate potential ... --> The PREVENT Cancer Drug Development Program is ...
(Date:10/29/2015)... health pioneer, Joseph C. Kvedar , MD, describes ... wellness, and the business opportunities that arise from it ... Healthy Things . Long before health and wellness ... vice president, Connected Health, Partners HealthCare, was creating a ... the hospital or doctor,s office into the day-to-day lives ...
(Date:10/27/2015)... SAN JOSE, Calif. , Oct. 27, 2015 /PRNewswire/ ... human interface solutions, today announced that Google has adopted ... family of touch controller solutions to power its newest ... Nexus 6P by Huawei. --> ... ecosystem partners like Google to provide strategic collaboration in ...
Breaking Biology News(10 mins):